ESMO 2022 | IMvigor130: a post-hoc analysis of atezolizumab monotherapy in urothelial carcinoma

Enrique Grande, MD, PhD, MSc, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses a post-hoc analysis of the Phase III IMvigor130 (NCT02807636) trial which explored atezolizumab as monotherapy and in combination with platinum-based chemotherapy in participants with untreated locally advanced or metastatic urothelial carcinoma, demonstrating a trend in favorable overall-survival (OS) with atezolizumab monotherapy. In this post-hoc analysis, the immunological basis underlying the trend in favorable OS with atezolizumab monotherapy was investigated, through studying associations between two PD-L1 immunohistochemistry tests (VENTANA SP142 and Dako 22C3) and OS in patients with archival tumors in IMvigor130. Different OS trends were observed with different PD-L1 assays. PD-L1–expressing DCs may underlie the longer OS with atezolizumab in SP142 IC2/3 versus IC0/1 tumours in patients with mUC. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.